<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363809">
  <stage>Registered</stage>
  <submitdate>13/03/2013</submitdate>
  <approvaldate>20/03/2013</approvaldate>
  <actrnumber>ACTRN12613000315718</actrnumber>
  <trial_identification>
    <studytitle>Effects of dust mite sublingual immunotherapy in children with allergic rhinitis.</studytitle>
    <scientifictitle>Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house dust mites:  A Double-Blind-Placebo-Controlled Randomised Trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Allergic Rhinitis</healthcondition>
    <healthcondition>Allergic conjunctivitis</healthcondition>
    <healthcondition>Bronchial hyper-responsiveness</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Allergies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subjects were randomized to receive active sublingual immunotherapy or placebo using a double-blind method. Active Sublingual immunotherapy containing 300 Index of Reactivity/mL of Dermatophagoides pteronyssinus and Dermatophagoides farinae 50:50% or placebo. Both active sublingual immunotherapy and placebo were administered sublingually with 8 drops/once a day 3 times a week, for a 12 months treatment duration.</interventions>
    <comparator>Placebo group act as a control. Placebo contained solution as in the active immunotherapy without active allergen extract (Dermatophagoides pteronyssinus and Dermatophagoides farinae 50:50%). Given as sublingual drops. </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Total rhinitis symproms scores. Using symptoms scores questionnaire evaluating sneezing, itchy, rhinorhea and blockage according to its severity. None=0, mild=1, moderate=2 and severe=3. </outcome>
      <timepoint>12 months after randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Conjunctivitis symptom scores. Using symptom scores questionnaire evaluating, eye redness, itchy and watery.</outcome>
      <timepoint>12 months after randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Medication scores. Using medication scores questionnaire.</outcome>
      <timepoint>12 months after randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pulmonary function tests. Using spirometry to assess lung function.</outcome>
      <timepoint>12 months after randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Allergen specific nasal provocation test. Using house dust mite allergen extract, patients were provoked producing rhinitis symptoms. </outcome>
      <timepoint>12 months after randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bronchial reactivity. Using methacholine provocation test.</outcome>
      <timepoint>12 months after randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children aged between 5-10 years of both genders with the history of persistent allergic rhinitis without asthmatic symptoms.</inclusivecriteria>
    <inclusiveminage>5</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>10</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Allergic asthma, previous allergen immunotherapy, chronic disease, malignancy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/11/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Marmara University medical faculty</primarysponsorname>
    <primarysponsoraddress>Marmara Universitesi Rektorluk Binasi BAPKO 34722 Goztepe Istanbul</primarysponsoraddress>
    <primarysponsorcountry>Turkey</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Marmara University medical faculty</fundingname>
      <fundingaddress>Marmara Universitesi Rektorluk Binasi BAPKO 34722 Goztepe Istanbul</fundingaddress>
      <fundingcountry>Turkey</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Double-blind randomized placebo controlled trial of children with persistant rhinitis, allergic to dust mites were included. All evaluationwas done at baseline and 12 months after randomisation as for clinical status, bronchial and nasal hyper-reactivity.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Marmara University Ethical Comittee</ethicname>
      <ethicaddress>Marmara Universitesi Tip Fakultesi Deontoloji BD Haydarpasa 34668</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Turkey</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Metin Aydogan</name>
      <address>Marmara University Pendik EAH Fevzi cakmak Mh Pendik Istanbul 34890
</address>
      <phone>+90568963256</phone>
      <fax />
      <email>mmetinaydogan@hotmail.com</email>
      <country>Turkey</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Metin Aydogan</name>
      <address>Marmara University Pendik EAH Fevzi cakmak Mh Pendik Istanbul 34890
</address>
      <phone>+90568963256</phone>
      <fax />
      <email>mmetinaydogan@hotmail.com</email>
      <country>Turkey</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Metin Aydogan</name>
      <address>Marmara University Pendik EAH Fevzi cakmak Mh Pendik Istanbul 34890
</address>
      <phone>+90568963256</phone>
      <fax />
      <email>mmetinaydogan@hotmail.com</email>
      <country>Turkey</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>